Search Results

You are looking at 21 - 30 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

Philip W. Kantoff and James L. Mohler

aggressive disease, PSA kinetics are informative. Active surveillance is an appropriate option for men with clinically localized prostate cancer when the PSA doubling time exceeds 5 years, he said. In determining treatment (and in discussions with patients

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Maria Ho

other factors (eg, age, ethnicity, family history, PSA kinetics) should also inform the decision to perform a biopsy. Several panel members also noted that risk calculators could be used in appropriately selected men. These calculators have been

Full access

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, and Ines Vaz-Luis

testing. Abbreviation: TM, tumor marker. workup for metastatic disease. 5 Nevertheless, in both, TM testing is given as an option for monitoring mBC. 5 , 10 The kinetics of CEA and CA 15-3 have been retrospectively correlated with treatment

Full access

Dung T. Le and Elizabeth M. Jaffee

-Tricom vaccine, 18 patients who were predicted to have indolent disease using the Halabi prediction nomogram 19 lived a median of more than 37.3 months. This suggests that if the kinetics of tumor growth outpace the kinetics of immune induction, then

Full access

Shailender Bhatia and John A. Thompson

routine use of maintenance dosing of ipilimumab is currently not recommended, although reinduction doses may be considered at disease progression in patients who have clearly benefitted from induction doses of ipilimumab. Response Kinetics and Patterns

Full access

David Y. Oh, Alan P. Venook, and Lawrence Fong

to future investigations of CRC immunotherapy. Clinical Considerations With Immunotherapies The kinetics of clinical responses can be very different with immunotherapies. A common feature of several of the approved immune therapies (in

Full access

Chezi Ganzel, Dan Douer, and Martin S. Tallman

PML/RARα Analysis in a Patient Treated With ATO The kinetics of leukemia cell clearance after the use of ATO is significantly different from that of ATRA-based therapy. Thus, a group from India tried to explore, prospectively, the most informative

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades, and Kenneth C. Anderson

factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma . Blood 2005 ; 106 : 3777 – 3784 . 51. Richardson PG Briemberg H Jagannath S . Frequency, characteristics, and reversibility of

Full access

Michael Angarone and Michael G. Ison

-load kinetics to identify patients who develop cytomegalovirus disease after transplantation . Lancet 2000 ; 355 : 2032 – 2036 . 51. Ljungman P Aschan J Lewensohn-Fuchs I . Results of different strategies for reducing cytomegalovirus

Full access

Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti, and Ketki K. Tendulkar

: 1376 – 1385 . 3. Weber JS Kahler KC Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab . J Clin Oncol 2012 ; 30 : 2691 – 2697 . 4. Weber JS Dummer R de Pril V . Patterns of onset